Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Stuttgart - Delayed Quote EUR

Biogen Inc (IDP.SG)

Compare

134.15

-0.35

(-0.26%)

At close: February 28 at 4:24:20 PM GMT+1

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti-Aβ monoclonal antibody lecanemab, adopted in November 2024.1 Following CHMP's reaffirmation, after having considered the additional inform

PR Newswire yesterday

BIIB
Biogen Inc. (BIIB): Among the Stocks That Will Go to The Moon According to Analysts

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other stocks. The Stock Market Under Trump Admin While stocks initially fell based on worries regarding Trump tariffs on America’s […]

Insider Monkey 4 days ago

BIIB
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side effects. At Charing Cross Hospital in London, about 170 multiple sclerosis patients experienced complications, including relapses, mobility issues, fatigue, pain, and weight gain. Some cases were severe enough to require hospitalization. Also Read: Biogen Strengthens Pipeline With Stoke Therapeutic’s Dra

Benzinga 5 days ago

BIIB
Biogen Inc. (BIIB): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other pharmaceutical stocks. The Evolving Landscape of Healthcare and Biopharma Innovation Almost no other industry goes as far as the phrase “defensive” […]

Insider Monkey 6 days ago

BIIB
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment

Stoke will obtain a $165m upfront payment from Biogen upon completion of the transaction.

Pharmaceutical Technology 10 days ago

STOK

BIIB
We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative

Biogen Inc.'s ( NASDAQ:BIIB ) recent earnings report didn't offer any surprises, with the shares unchanged over the...

Simply Wall St. 10 days ago

BIIB
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal

On Tuesday, Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to develop and commercialize zorevunersen for Dravet syndrome in all territories outside the United States, Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Stoke recently announced plans to initiate a global Phase 3 registrational study of zorevunersen (EMPEROR) following the alignm

Benzinga 10 days ago

STOK

BIIB
$Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments$

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

CAMBRIDGE, Mass. & BEDFORD, Mass., February 18, 2025--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the development and commercialization of zorevunersen, a potential first-in-class disease modifying medicine in development for the treatment of Dravet syndrome, in all territories outside the United States, Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying

Business Wire 11 days ago

STOK

BIIB
Biogen buys rights to Stoke’s rare epilepsy drug

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet syndrome.

BioPharma Dive 11 days ago

BIIB

STOK
Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts

On Wednesday, Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over year on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion. Needham analyst Ami Fadia expects challenges in the multiple sclerosis segment, as growth from key product launches isn’t enough to make up for declines. While Leqembi sales performed well outside the U.S. and Skyclarys

Benzinga 15 days ago

BIIB
Biogen Still Offering Value, RBC Says

Biogen (BIIB) showed how it has "successfully" reprioritized R&D and rightsized operating expenses i

PREMIUM
MT Newswires 15 days ago

BIIB
Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance

GILD and BIIB are in the spotlight this week on fourth-quarter earnings release and outlook for 2025.

Zacks 16 days ago

BIIB

GILD
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank

Scotiabank lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps an Outperform rating on the shares. The firm’s rating remains Outperform based on its belief that the company will be sold to Biogen (BIIB) at a significant premium, the analyst tells investors. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on SAGE: Sage Therapeutics price target lowere

TipRanks 16 days ago

BIIB

SAGE
Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

BioPharma Dive 16 days ago

BIIB

ABBV

NMRA
Royalty Pharma pays $250m for rights to Biogen’s lupus drug

The deal comes as Biogen reports its Q4 2024 earnings.

Pharmaceutical Technology 16 days ago

BIIB

GLDAF
Biogen Full Year 2024 Earnings: EPS Misses Expectations

Biogen ( NASDAQ:BIIB ) Full Year 2024 Results Key Financial Results Revenue: US$9.68b (down 1.6% from FY 2023). Net...

Simply Wall St. 16 days ago

BIIB
Biogen Inc (BIIB) Q4 2024 Earnings Call Highlights: Strong EPS Growth Amid Revenue Challenges

Biogen Inc (BIIB) reports a 17% increase in Q4 EPS, driven by new product launches, despite facing revenue declines and competitive pressures.

GuruFocus.com 16 days ago

BIIB
Q4 2024 Biogen Inc Earnings Call

Q4 2024 Biogen Inc Earnings Call

Thomson Reuters StreetEvents 16 days ago

BIIB
Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat

Biogen stock took a hit Wednesday after the biotech company issued light guidance for 2025 despite beating most fourth-quarter expectations.

Investor's Business Daily 16 days ago

BIIB
Biogen (BIIB) Q4 2024 Earnings Call Transcript

BIIB earnings call for the period ending December 31, 2024.

Motley Fool 16 days ago

BIIB

Performance Overview

Return	IDP.SG	S&P 500
YTD	-7.42%	+1.24%
1-Year	-34.94%	+17.45%
3-Year	-27.58%	+36.14%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Biogen Inc (IDP.SG)

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

Biogen Inc. (BIIB): Among the Stocks That Will Go to The Moon According to Analysts

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects

Biogen Inc. (BIIB): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts

Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment

We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Biogen buys rights to Stoke’s rare epilepsy drug

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts

Biogen Still Offering Value, RBC Says

Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance

Sage Therapeutics price target lowered to $12 from $14 at Scotiabank

Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

Royalty Pharma pays $250m for rights to Biogen’s lupus drug

Biogen Full Year 2024 Earnings: EPS Misses Expectations

Biogen Inc (BIIB) Q4 2024 Earnings Call Highlights: Strong EPS Growth Amid Revenue Challenges

Q4 2024 Biogen Inc Earnings Call

Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat

Biogen (BIIB) Q4 2024 Earnings Call Transcript

Performance Overview